Program Description
Transthyretin amyloidosis (ATTR) is a life-threatening, progressive, and underrecognized disease characterized by misfolded transthyretin protein that can present with cardiac, neurologic, or mixed phenotypes. ATTR causes significant multisystem burden, and proper management requires accurately differentiating between the various types. Advances in research have contributed to the development of disease-modifying therapies (DMTs) to manage ATTR; however, more research is needed to recognize safety and efficacy, as long-term therapy with these medications may cause treatment barriers. This program will focus on DMTs and investigational therapies for ATTR-cardiomyopathy and ATTR-polyneuropathy, equipping pharmacists to identify ATTR clinical presentation, optimize treatment regimens, and improve patients' health and quality of life. Practical aspects of patient education, therapy adjustments based on lab values, interpretation of relevant laboratory results, and tailoring treatment to individual patient presentations will also be discussed.
Target audience: Health System Pharmacist
Type of activity: Application
Release date: June 30, 2025
Expiration date: June 30, 2026
Time to complete activity: 1.0 hour
Learner level: Foundational
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Identify the clinical manifestations of transthyretin amyloidosis (ATTR)
- Explore the treatment recommendations for ATTR
- Explain treatment plan recommendations for patients presenting with ATTR-CM, ATTR-PN, and mixed phenotype ATTR
- Provide opportunities for pharmacists to support multidisciplinary interventions for ATTR patients
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here